We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

18 hedge funds and large institutions have $8.95M invested in Arbutus Biopharma in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

64% more funds holding

Funds holding: 11 → 18 (+7)

47% more capital invested

Capital invested by funds: $6.09M → $8.95M (+$2.87M)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
18
Holders Change
+7
Holders Change %
+63.64%
% of All Funds
0.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KA
Kerrisdale Advisers
Florida
+$300K
2
Deutsche Bank
Deutsche Bank
Germany
+$253K
3
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
+$189K
4
OAM
Orinda Asset Management
California
+$66K
5
LOM
Loeb Offshore Management
New York
+$55.1K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$609K
2
IGIM
I.G. Investment Management
Manitoba, Canada
-$475K
3
SIM
Spark Investment Management
New York
-$13.2K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$4.29K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
1
Bank of Montreal
Ontario, Canada
$5.55M +$49.8K +9,041 +1%
PA
2
Perceptive Advisors
New York
$1.11M -$609K -110,691 -41%
KA
3
Kerrisdale Advisers
Florida
$626K +$300K +54,497 +153%
IGIM
4
I.G. Investment Management
Manitoba, Canada
$445K -$475K -86,250 -58%
Deutsche Bank
5
Deutsche Bank
Germany
$319K +$253K +46,000 New
AWMDMG
6
Austin W. Marxe & David M. Greenhouse
New York
$239K +$189K +34,270 New
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$127K -$4.29K -780 -4%
SKK
8
Shepherd Kaplan Krochuk
Massachusetts
$121K – – –
VKH
9
Virtu KCG Holdings
New York
$92K +$73K +13,252 New
OAM
10
Orinda Asset Management
California
$84K +$66K +11,979 New
SIM
11
Spark Investment Management
New York
$71K -$13.2K -2,400 -19%
LOM
12
Loeb Offshore Management
New York
$70K +$55.1K +10,000 New
FANJ
13
Financial Architects (New Jersey)
New Jersey
$63K – – –
HCM
14
Highlander Capital Management
New Jersey
$13.9K +$11K +2,000 New
TRCT
15
Tower Research Capital (TRC)
New York
$9K +$7.08K +1,285 New
U
16
UBS
Switzerland
$8K +$6.55K +1,189 New
Barclays
17
Barclays
United Kingdom
$2K +$551 +100 +33%
Wells Fargo
18
Wells Fargo
California
$1K – – –

ABUS Hedge Fund Activity: Q3 2013 in Review

18 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2013, worth a combined $8.95M — up 47% from $6.09M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ABUS positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Kerrisdale Advisers, adding an estimated $300K. The largest seller was Perceptive Advisors, cutting an estimated $609K.

  • 18 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2013, up from 11 in Q2 2013.
  • Funds reported $8.95M of Arbutus Biopharma stock for Q3 2013, up 47% quarter-over-quarter.
  • 8 funds opened new Arbutus Biopharma positions in Q3 2013 and 1 closed out, a net change of +7 holders.
  • The largest Arbutus Biopharma buyer in Q3 2013 was Kerrisdale Advisers, an estimated $300K added.
  • The largest Arbutus Biopharma seller in Q3 2013 was Perceptive Advisors, an estimated $609K sold.

Based on aggregated 13F filings for Q3 2013.